Objective To evaluate the safety and efficacy of elagolix vs. placebo and elagolix with low-
dose E 2/progestogen add-back therapy. Design Proof-of-concept, dose-ranging, multiple …

Background Uterine fibroids are hormone-responsive neoplasms that are associated with
heavy menstrual bleeding. Elagolix, an oral gonadotropin-releasing hormone antagonist …

Background Uterine fibroids are one of the most common neoplasms found among women
globally, with a prevalence of approximately 11 million women in the United States alone …

Objective To determine if coexisting adenomyosis limits the efficacy of elagolix, an oral
gonadotropin-releasing hormone antagonist, with hormonal add-back therapy in reducing …

ABSTRACT Introduction Uterine fibroids (UFs) are the most common benign tumor arising
from myometrium of reproductive age women, with significant financial burden estimated in …

OBJECTIVE: To investigate the safety and efficacy of elagolix, an oral gonadotropin-
releasing hormone antagonist, with hormonal add-back therapy for up to 12 months in …

Background Uterine fibroids are a common cause of heavy menstrual bleeding and pain.
Treatment with the combination of relugolix (an oral gonadotropin-releasing hormone …

OBJECTIVE: To evaluate elagolix, an oral gonadotropin-releasing hormone receptor
antagonist, alone or with add-back therapy, in premenopausal women with heavy menstrual …

Background Uterine fibroids are common non-cancerous neoplasm that cause heavy
menstrual bleeding and other signs. Linzagolix is an oral gonadotropin-releasing hormone …

STUDY QUESTION Can asoprisnil, a selective progesterone receptor modulator, provide
clinically meaningful improvements in heavy menstrual bleeding (HMB) associated with …